Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI® (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).
The TOBI® (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.
Dr. Reddy's Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule.
Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.2511.8 as compared to the previous close of Rs. 2549.95. The total number of shares traded during the day was 25683 in over 1356 trades.
The stock hit an intraday high of Rs. 2542 and intraday low of 2503.3. The net turnover during the day was Rs. 64654498.
Tobi® is a trademark of Mylan.